Search details
1.
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19.
Mol Ther
; 31(3): 788-800, 2023 03 01.
Article
in English
| MEDLINE | ID: mdl-36575794
2.
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective.
Int J Mol Sci
; 24(15)2023 Jul 25.
Article
in English
| MEDLINE | ID: mdl-37569269
3.
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells.
Int J Mol Sci
; 24(22)2023 Nov 14.
Article
in English
| MEDLINE | ID: mdl-38003483
4.
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC).
Int J Mol Sci
; 24(6)2023 Mar 20.
Article
in English
| MEDLINE | ID: mdl-36982938
5.
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients.
Anticancer Drugs
; 33(1): e628-e634, 2022 01 01.
Article
in English
| MEDLINE | ID: mdl-34407044
6.
Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic.
Eur J Clin Pharmacol
; 78(11): 1791-1800, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36102931
7.
Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study.
BMC Public Health
; 22(1): 2137, 2022 11 21.
Article
in English
| MEDLINE | ID: mdl-36411406
8.
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9).
Breast Cancer Res Treat
; 190(1): 103-109, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-34453206
9.
Methotrexate inhibits SARS-CoV-2 virus replication "in vitro".
J Med Virol
; 93(3): 1780-1785, 2021 03.
Article
in English
| MEDLINE | ID: mdl-32926453
10.
Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study.
BMC Cancer
; 21(1): 260, 2021 Mar 10.
Article
in English
| MEDLINE | ID: mdl-33691674
11.
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale.
Eur J Cancer Care (Engl)
; 30(1): e13334, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-33015898
12.
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
J Cell Physiol
; 235(11): 7900-7910, 2020 11.
Article
in English
| MEDLINE | ID: mdl-31943171
13.
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
Breast Cancer Res
; 22(1): 114, 2020 10 27.
Article
in English
| MEDLINE | ID: mdl-33109210
14.
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast Cancer Res
; 22(1): 9, 2020 Jan 22.
Article
in English
| MEDLINE | ID: mdl-31969184
15.
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Int J Cancer
; 146(7): 1917-1929, 2020 04 01.
Article
in English
| MEDLINE | ID: mdl-31330065
16.
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
BMC Cancer
; 20(1): 232, 2020 Mar 19.
Article
in English
| MEDLINE | ID: mdl-32188417
17.
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
J Cell Physiol
; 234(6): 7708-7717, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30536609
18.
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast Cancer Res
; 21(1): 133, 2019 12 03.
Article
in English
| MEDLINE | ID: mdl-31796073
19.
Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.
Oncologist
; 24(6): e232-e240, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30413667
20.
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success.
Breast Cancer Res Treat
; 176(3): 483-494, 2019 Aug.
Article
in English
| MEDLINE | ID: mdl-31065872